Related by context. All words. (Click for frequent words.) 74 Daclizumab 74 Temsirolimus 73 Dasatinib 73 Everolimus 73 Bevacizumab 73 Clofarabine 73 Aflibercept 73 Etanercept 72 Trastuzumab 72 Campath alemtuzumab 72 YONDELIS 72 Nilotinib 72 Erlotinib 71 Golimumab 71 Pertuzumab 71 Campath ® 71 Fabry Disease 71 Bortezomib 71 Amrubicin 71 Pirfenidone 71 Gleevec imatinib mesylate 71 Meets Primary Endpoint 71 Lenalidomide 71 Ofatumumab 71 Pemetrexed 70 Epratuzumab 70 Vandetanib 70 Lupus Nephritis 70 Fingolimod 70 Myelodysplastic Syndrome MDS 70 Oxaliplatin 70 Romiplostim 70 Gleevec resistant 70 gefitinib Iressa 70 Velcade bortezomib 70 Pralatrexate 70 Maribavir 70 Pivotal Phase III 70 erlotinib Tarceva ® 70 AVASTIN 70 Fludarabine 70 relapsing remitting MS RRMS 70 Glatiramer Acetate 70 Laquinimod 70 Degarelix 69 Investigational Treatment 69 Irinotecan 69 proteasome inhibitor 69 Nexavar ® 69 Severe Sepsis 69 Panitumumab 69 Renal Cell Carcinoma 69 Naive Patients 69 Xanafide 69 Eculizumab 69 Gefitinib 69 efalizumab 69 metastatic malignant 69 Boceprevir 69 Tocilizumab 69 Hepatocellular Carcinoma HCC 69 Arranon 69 Ocrelizumab 69 Natalizumab 69 recurrent glioblastoma multiforme 69 Azacitidine 69 Tanespimycin 69 AMN# [001] 69 Tyrosine Kinase Inhibitor 69 Romidepsin 69 Imatinib 69 Sorafenib 69 sorafenib tablets 69 Myelofibrosis 69 Elotuzumab 69 Advanced Melanoma 69 Bendamustine 69 Plicera 69 Fludara ® 69 CYT# potent vascular disrupting 69 Voreloxin 69 Hepatocellular Carcinoma 68 SPRYCEL ® 68 Adalimumab 68 Certolizumab pegol 68 sorafenib Nexavar 68 AVONEX ® 68 Aliskiren 68 relapsing multiple sclerosis 68 bevacizumab Avastin 68 Combination REOLYSIN R 68 Cloretazine 68 Gemzar ® 68 Anthracycline 68 Talabostat 68 Omacetaxine 68 Myelodysplastic Syndromes 68 Metastatic Colorectal Cancer 68 dasatinib Sprycel 68 LEUKINE 68 rituximab Rituxan 68 Anti VEGF 68 Cutaneous T 68 Rituximab 68 Blinatumomab 68 Fulvestrant 68 Prolongs Survival 68 Cladribine 68 dirucotide MBP# 68 GW# [003] 68 Pazopanib 68 Dalbavancin 68 relapsed leukemia 68 lupus nephritis 68 Rilonacept 68 Chronic Lymphocytic Leukemia 68 Neulasta ® 68 BARACLUDE ® 68 Vidaza azacitidine 68 Ambrisentan 68 UPLYSO 68 HuMax CD4 68 Patients Treated With 68 Pixantrone 68 Tamibarotene 68 Phase III Trials 68 Paraplatin ® 68 Herceptin trastuzumab 68 Adjuvant Treatment 68 Decitabine 68 IL# PE#QQR 68 Telbivudine 68 thalidomide Thalomid 68 etanercept Enbrel 68 TYZEKA 67 icatibant 67 Safinamide 67 Arimoclomol 67 PD LID 67 Progressive Multifocal Leukoencephalopathy 67 Pivotal Phase 67 Hsp# Inhibitor 67 Phase III Trial 67 Nitazoxanide 67 refractory chronic lymphocytic 67 Abatacept 67 decitabine 67 antibody MAb 67 Phase 2a Trial 67 PEGylated Fab fragment 67 Arcalyst 67 Phase 2b Clinical Trial 67 receptor tyrosine kinase inhibitor 67 Noxafil 67 dasatinib Sprycel ® 67 Bosutinib 67 Ixempra 67 Ceflatonin 67 Gemcitabine 67 Temodar ® 67 Ranibizumab 67 HER2 Positive Breast Cancer 67 Sanofi Aventis Taxotere 67 MyVax R 67 Disease Progression 67 EVIZON TM 67 Unresectable 67 Silodosin 67 Clolar ® 67 Overactive Bladder 67 Raptiva ® 67 Monotherapy 67 Anastrozole 67 adalimumab Humira 67 ACZ# 67 Tigecycline 67 Zolinza 67 imatinib Gleevec ® 67 INCB# [001] 67 Docetaxel 67 pegylated interferons 67 Idiopathic Pulmonary Fibrosis 67 IRESSA 67 Arzerra ofatumumab 67 Randomized Phase 67 Trabectedin 67 Revlimid lenalidomide 67 abatacept Orencia 67 Tesmilifene 67 Roche Actemra 67 FASLODEX 67 hematological malignancy 67 AA Amyloidosis 67 ORENCIA R 67 Riluzole 67 Novantrone 67 lumiliximab 67 Phase IIb Trial 67 TYKERB 67 alefacept 67 Granulocyte Colony Stimulating Factor 67 Sapacitabine 67 Vicriviroc 67 Palifosfamide 67 Sebivo 67 Ozarelix 67 Iloperidone 67 Investigational Compound 67 Ustekinumab 67 investigational monoclonal antibody 67 TREANDA 67 Orphan Status 67 Complicated Skin 67 Pfizer Sutent 67 Exemestane 67 gastrointestinal stromal tumors 67 TNF Tumor Necrosis Factor 67 Febuxostat 67 Ceflatonin R 67 hypereosinophilic syndrome 67 Cetrorelix 67 Epidermal Growth Factor Receptor 67 Kepivance 67 BAY #-# 67 Novartis Gleevec 67 Abacavir 67 cetuximab Erbitux R 67 Tolvaptan 67 Combo Therapy 67 Treatment Resistant 67 Pulmonary Arterial Hypertension 67 Pegylated 67 JAK Inhibitor 67 Elagolix 67 Psoriasis Drug 67 CDP# 66 erlotinib Tarceva 66 Roche Xeloda 66 Relapsed Refractory 66 docetaxel Taxotere ® 66 ZOLINZA 66 canakinumab 66 Genentech Rituxan 66 mertansine 66 romiplostim 66 alemtuzumab 66 Methylnaltrexone 66 Daptomycin 66 Chronic Myeloid Leukemia 66 AGILECT R 66 reslizumab 66 cutaneous T 66 Oral Fingolimod 66 Ridaforolimus 66 Tacrolimus 66 Glufosfamide 66 biologic therapy 66 Clinical Trial Results 66 Aviptadil 66 Diabetic Macular Edema 66 eosinophilic asthma 66 Pegylated Interferon 66 Phase IIb Clinical Trial 66 nilotinib Tasigna 66 FOLOTYN ® 66 Perifosine 66 YONDELIS R 66 Tipranavir 66 Dapagliflozin 66 Antitumor Activity 66 Previously Untreated 66 Hormone Refractory Prostate Cancer 66 targeting CD# 66 anticancer therapy 66 relapsing remitting multiple sclerosis 66 MAGE A3 ASCI 66 Peginterferon 66 Xelox 66 Bevacizumab Avastin 66 PKC# 66 rasagiline tablets 66 Improves Survival 66 Omalizumab 66 Neoadjuvant 66 Mitoxantrone 66 imatinib Gleevec 66 Navelbine ® 66 Omnitarg 66 Mipomersen 66 calcineurin inhibitors 66 Metastatic Prostate Cancer 66 rilonacept 66 Crizotinib 66 Traficet EN 66 Rheumatoid Arthritis Drug 66 Ecallantide 66 Entecavir 66 Chronic lymphocytic leukemia 66 Certolizumab 66 Pegloticase 66 Allergic Rhinitis 66 phase IIb trial 66 Tyrosine Kinase Inhibitors 66 Hedgehog Pathway Inhibitor 66 ACTEMRA TM 66 Lubiprostone 66 Previously Treated 66 interferon gamma 1b 66 DEB# 66 oral FTY# 66 vemurafenib 66 Torisel 66 Elvitegravir 66 nucleoside analogue 66 Enzyme Replacement Therapy 66 Rheumatoid Arthritis Patients 66 Fondaparinux 66 Initiates Phase III 66 invasive candidiasis 66 Interferon Beta 66 Immunotherapeutic 66 RhuDex ® 66 Antiangiogenic 66 Tarceva erlotinib 66 Diabetic Neuropathy 66 Bucindolol 66 Glivec imatinib 66 SJIA 66 Hycamtin 66 Tarceva TM 66 Civacir 66 trabectedin 66 teriflunomide 66 tolevamer 66 Follicular Lymphoma 66 DU #b 66 Cethromycin 66 XYOTAX TM 66 Malignant Melanoma 66 Long Term Efficacy 66 Adentri 66 metastatic kidney 66 Etravirine 66 Cethrin 66 Cariprazine 66 gastrointestinal stromal tumors GIST 66 rheumatoid arthritis psoriatic arthritis 66 Pivotal Clinical Trial 66 Fluconazole 66 Vidofludimus 66 TEMODAL 66 Survival Benefit 66 BRAF inhibitor 66 Genasense ® 66 Adjuvant Chemotherapy 66 Initiates Clinical 66 ZEVALIN ® 66 HQK 66 pertuzumab 66 Tasigna nilotinib 66 phase IIb clinical 66 lenalidomide Revlimid R 66 MEK Inhibitor 66 Factor VIIa 66 herpetic keratitis 66 Initiates Enrollment 66 Leukemias 66 KRN# 66 Platinol ® 66 Initiate Phase 66 Patient Enrollment 66 Drug Candidate 66 chronic eosinophilic leukemia 66 sunitinib malate 66 BARACLUDE R 66 Sipuleucel T 66 bevacizumab Avastin ® 66 Teriflunomide 66 huC# DM4 66 Soft Tissue Sarcoma 66 Newly Diagnosed Multiple Myeloma 66 Belimumab 66 hepatitis C HCV 66 Chronic Lymphocytic Leukemia CLL 65 INCB# [003] 65 Anti TNF 65 Mylotarg 65 Interferon beta 65 PEGylated interferon beta 1a 65 SNT-MC#/idebenone 65 malignant pleural mesothelioma 65 Dacogen decitabine 65 cetuximab Erbitux 65 RhuDex 65 FTY# 65 leukemia AML 65 Vitaxin 65 Prostate Cancer Vaccine 65 Bafetinib 65 Liprotamase 65 Carfilzomib 65 infliximab Remicade 65 Fast Track Status 65 Tavocept 65 Clevudine 65 Interferon Alpha 65 Tiotropium 65 SinuNase TM 65 Tezampanel 65 acyclovir Lauriad R 65 Bezielle 65 Rilutek 65 tyrosine kinase inhibitor 65 Angioedema 65 Myelodysplastic Syndrome 65 Pooled Analysis 65 Improves Outcomes 65 Investigational Agent 65 recurrent NSCLC 65 PrevOnco 65 abacavir Ziagen 65 Lung Cancer Drug 65 Campath 65 Tofacitinib 65 xanthine oxidase inhibitor 65 HCV Protease Inhibitor 65 Drug Shows Promise 65 tocilizumab 65 Relapsed Multiple Myeloma 65 ixabepilone 65 R lenalidomide 65 Eraxis 65 selective modulator 65 Rituxan rituximab 65 Pafuramidine 65 Deforolimus 65 pediatric Crohn disease 65 vismodegib 65 nilotinib 65 Interferon beta 1a 65 LAF# 65 Ixabepilone 65 Taxanes 65 Ramelteon 65 bendamustine 65 Phase III Clinical Trial 65 Humira adalimumab 65 Pharmacokinetics PK 65 Rotigotine 65 panitumumab Vectibix 65 Brentuximab Vedotin SGN 65 Achieves Primary Endpoint 65 Modrenal R 65 relapsed MM 65 Tasimelteon 65 Maraviroc 65 Relapsing Remitting Multiple Sclerosis 65 Catena ® 65 Gleevec imatinib 65 ACE Inhibitors 65 Nexavar sorafenib 65 angiogenesis inhibitor 65 visilizumab 65 RAPTIVA 65 Clolar 65 Cimzia TM 65 pediatric acute lymphoblastic 65 SUTENT 65 BRIM2 65 Completes Patient Enrollment 65 beta 1a 65 Advanced Renal Cell 65 Lamotrigine 65 STELARA TM 65 Sprycel dasatinib 65 LymphoStat B belimumab 65 Avastin bevacizumab 65 Diffuse Large B 65 Adjuvant Therapy 65 cladribine 65 PEGylated anti 65 atypical Hemolytic Uremic Syndrome 65 vandetanib 65 mesylate 65 Actemra tocilizumab 65 sunitinib Sutent 65 terlipressin 65 oral dual endothelin 65 Gout Drug 65 Leukine 65 Thalomid ® 65 nonsmall cell lung cancer 65 Treanda 65 galiximab 65 Receives Orphan Drug Designation 65 Certican 65 Infliximab 65 systemic fungal infections 65 LymphoStat B 65 Biogen Idec Avonex 65 Carboplatin 65 Taxotere ® 65 Parnate 65 COPAXONE R 65 ELND# 65 PegIFN RBV 65 PEGINTRON TM 65 Castration Resistant Prostate Cancer 65 baminercept 65 Cabazitaxel 65 Phase 2b Trial 65 Milnacipran 65 RoACTEMRA 65 Leukine ® 65 Lung Cancer Patients 65 OvaRex ® MAb 65 Darinaparsin 65 Patients Receiving 65 proteasome inhibitors 65 hypomethylating agents 65 sertraline Zoloft 65 Teriparatide 65 Chemoradiation 65 adult chronic ITP 65 Subgroup Analysis 65 glatiramer 65 IV Busulfex 65 Dacogen injection 65 Nimotuzumab 65 TELINTRA 65 Gastric Cancer 65 Vfend 65 Phase #b/#a clinical 65 sargramostim 65 IMiDs ® compound 65 Evoltra 65 ImClone Erbitux 65 Moxifloxacin 65 Pivotal Trial 65 fibromyalgia syndrome 65 Lymphocytic 65 R sorafenib tablets 65 systemic juvenile idiopathic 65 novel VDA molecule 65 Ticagrelor 65 BCR ABL inhibitors 65 ganetespib 65 Efficacy Trial 65 Valopicitabine 65 Rheumatoid Arthritis RA 65 Treated Patients 65 Ganciclovir 65 vorinostat 65 Immunotherapies 65 Cetuximab 65 Pregabalin 65 Pegasys ® 65 Betaferon R 65 UCB Cimzia 65 cutaneous T cell 65 HDAC Inhibitor 65 thetreatment 65 CTAP# Capsules 65 BEXXAR 65 dasatinib 65 Hodgkin lymphoma HL 65 Tesamorelin 65 CCR5 receptor antagonist 65 NDA Submission 65 panobinostat 65 Mirapexin 65 Vectibix panitumumab 65 Lapatinib 65 Tegaserod 64 Lupus Drug 64 PROCRIT ® 64 Paliperidone Palmitate 64 Aptivus ® 64 Actemra 64 Tumor Necrosis Factor 64 Candesartan 64 Improved Survival 64 Cholesterol Lowering Drug 64 Firazyr 64 Jevtana 64 MGd 64 Sutent sunitinib 64 chimeric monoclonal antibody 64 CAELYX 64 ONGLYZA ™ 64 cell lymphoma CTCL 64 OHR/AVR# 64 histone deacetylase HDAC inhibitor 64 diabetic neuropathic pain 64 metastatic castration resistant 64 induced macular edema 64 Cinquil 64 chronic idiopathic thrombocytopenic purpura 64 aripiprazole Abilify 64 Ilaris 64 Letairis ambrisentan 64 Shows Efficacy 64 Helicobacter pylori eradication 64 EGFR inhibitors 64 Allovectin 7 ® 64 BRIM3 64 pan HDAC inhibitor 64 docetaxel Taxotere R 64 Personalized Immunotherapy 64 Telmisartan 64 Microplasmin 64 Cell Lymphoma 64 OMAPRO ™ 64 Phase 2a Clinical Trial 64 Phase III Clinical Trials 64 Diabetic Nephropathy 64 cilengitide 64 vWD 64 non metastatic osteosarcoma 64 Archexin 64 Hepatitis C Virus 64 myelodysplastic syndrome MDS 64 SHPT 64 immunomodulatory agents 64 Combination Treatment 64 Atypical Hemolytic Uremic Syndrome 64 Phase Ib IIa 64 mTOR inhibitor 64 RhuDex R 64 Slows Progression 64 bortezomib Velcade 64 Neuvenge 64 Therapeutic Vaccine 64 Cardiotoxicity 64 Rasagiline 64 Rivaroxaban 64 OncoVex 64 Gleevec Glivec 64 Raptiva R 64 Novel Oral 64 tigecycline 64 Telaprevir 64 Recombinant Human 64 guanfacine extended release 64 NICE Recommends 64 forodesine 64 superficial bladder cancer 64 Mg Usa 64 Hematological Malignancies 64 relapsed SCLC 64 Aplidin 64 evaluating mipomersen 64 cediranib 64 anti CD3 antibody 64 Eltrombopag 64 cidofovir 64 ara C 64 recombinant interferon 64 relapsed multiple myeloma 64 Granted Orphan Drug 64 Kit CD# positive 64 myelodysplastic myeloproliferative diseases 64 lapatinib Tykerb 64 Drug Fails 64 rufinamide 64 Doxorubicin 64 Betaferon ® 64 kidney urologic 64 Allovectin 7 64 advanced metastatic renal 64 SNT MC# 64 Oral Anticoagulant 64 ADP receptor antagonist 64 imatinib mesylate 64 Nesiritide 64 Orally administered 64 Bicifadine 64 HCV SPRINT 64 LY# [003] 64 myelofibrosis polycythemia vera 64 VEGF inhibitors 64 alemtuzumab Campath 64 AMEVIVE 64 Benign Prostatic Hyperplasia 64 Lacosamide 64 Autologous Stem Cell Transplantation 64 gastrointestinal stromal tumor GIST 64 investigational oral inhibitor 64 BCR ABL inhibitor 64 Cancidas 64 Cimzia ® certolizumab pegol 64 recurrent metastatic ovarian cancer 64 Denufosol 64 Rebif ® 64 Acute Heart Failure 64 relapsing forms 64 Gaucher Disease 64 Tysabri natalizumab 64 IgG1 monoclonal antibody 64 Reverset 64 VFEND 64 metastatic malignant melanoma 64 Lambert Eaton Myasthenic 64 Anidulafungin 64 Initiates Clinical Trial 64 Protease Inhibitor 64 Capecitabine 64 Copegus ribavirin 64 fingolimod 64 Saforis 64 Chronic Hepatitis B 64 MKC# MKC# PP 64 Onconase 64 Valsartan 64 metastatic neuroendocrine tumors 64 alkylating agent 64 Peginterferon alfa 2b 64 Metastatic Melanoma 64 Hydroxyurea 64 dirucotide 64 pegylated liposomal doxorubicin 64 MabCampath 64 basiliximab 64 Glioblastoma Multiforme 64 nucleoside analog 64 EOquin TM 64 Bayer Nexavar 64 phase III isavuconazole 64 Clostridium difficile Infection 64 Taxane 64 acadesine 64 MKC# MT 64 Emerging Therapies 64 biologic DMARD 64 metastatic renal cell carcinoma 64 Renal Cancer 64 briakinumab 64 Tetrabenazine 64 Anti Tumor Activity 64 natalizumab 64 Cholinesterase Inhibitors 64 methylnaltrexone 64 Squalamine 64 alfa 2a 64 Advanced Colorectal Cancer 64 Icatibant 64 Trastuzumab DM1 64 Olaparib 64 Zileuton 64 Yondelis ® 64 bosutinib 64 Atacicept 64 relapsed ALL 64 pegylated 64 Panzem R NCD 64 Annamycin 64 trastuzumab DM1 64 mRCC 64 Elderly Patients 64 Cimzia R 64 regorafenib 64 Adefovir 64 esophageal candidiasis 64 VIVITROL ® 64 developing Bicifadine serotonin 64 JAK inhibitor 64 recurrent ovarian cancer 64 nucleotide analogue 64 Zarnestra 64 azacitidine 64 Enzastaurin 64 RRMS patients 64 Lu AA# 64 Quinamed 64 clofarabine 64 Eribulin 64 Taxotere docetaxel 64 Dupuytren Contracture 64 tyrosine kinase inhibitors 64 Blood Pressure Drug 64 Avonex interferon beta 1a 64 evaluating tivozanib 64 gemcitabine Gemzar 64 Vivaglobin 64 Celgene Revlimid 64 Tekamlo 64 AEG# 64 hormone LHRH antagonist 64 Interferon beta 1b 64 Elesclomol 64 Carvedilol 64 Biogen Genentech 64 biologic antibody 64 advanced metastatic prostate 64 Serdolect ® 64 Treatment Shows Promise 64 Azathioprine 64 Vitrasert R 64 Apixaban 64 PROMACTA 64 glatiramer acetate 64 eltrombopag 64 Anti Tumor 64 MEVACOR 64 TTR amyloidosis 64 MEK inhibitor 64 Cilostazol 63 cisplatin chemotherapy 63 Randomized Study 63 AEGR 63 5 HT6 receptor 63 Chronic Sinusitis 63 Plaque Psoriasis 63 multiple myeloma MM 63 personalized cellular immunotherapy 63 daclizumab 63 calcineurin inhibitor 63 ISTODAX 63 Evoltra ® 63 Well Tolerated 63 Demonstrates Significant 63 Chronic Hepatitis C 63 ThermoDox R 63 Friedreich Ataxia FRDA 63 chemotherapeutic regimen 63 multi kinase inhibitor 63 interferon beta 1b 63 Raltegravir 63 Phase IIa Clinical Trial 63 haematologic 63 Fludara 63 targeted radiotherapeutic 63 Cyclophosphamide 63 daptomycin 63 Bayer HealthCare Onyx Pharmaceuticals 63 anakinra 63 Topotecan 63 Pradefovir 63 radiation sensitizer 63 Cimzia certolizumab pegol 63 Ranolazine 63 ZACTIMA 63 Transdermal Patch 63 oropharyngeal candidiasis 63 darapladib 63 PROCHYMAL 63 temsirolimus 63 idiopathic thrombocytopenic purpura ITP 63 Vidaza ® 63 venlafaxine Effexor 63 OPAXIO 63 raloxifene Evista 63 vinca alkaloid 63 interferon beta therapy 63 Mycamine 63 Removab 63 Phase IIb trials 63 ATL# [001] 63 Prospective Randomized 63 Phase III Pivotal 63 metastatic renal cell 63 acute HAE attacks 63 Satraplatin 63 Syndrome LEMS 63 Bipolar Depression 63 elacytarabine 63 COPAXONE ® 63 Malignant Glioma 63 Sevelamer 63 Cloretazine ® 63 rivastigmine Exelon 63 laquinimod 63 Cimzia ® 63 MBP# dirucotide 63 Monoclonal antibody 63 volociximab 63 Zorbtive TM 63 rheumatoid arthritis Crohn disease 63 refractory acute myeloid 63 Copegus ® 63 lymphoma CTCL 63 Doxil ® 63 Preclinical Models 63 Copegus R 63 IMiDs ® 63 Femara letrozole 63 PF # [002] 63 Pyridorin 63 microtubule inhibitor 63 CYP#A# substrate 63 Pimavanserin 63 Amigal 63 Systemic Delivery 63 cinacalcet 63 chronic lymphocytic leukemia CLL 63 Camptosar ® 63 trastuzumab DM1 T DM1 63 Acute Ischemic Stroke 63 ocrelizumab 63 Desvenlafaxine 63 GA GCB 63 Breast Cancer Treatment 63 Cysteamine 63 Systemic Sclerosis 63 sodium glucose cotransporter 63 paclitaxel Taxol R 63 Saxagliptin 63 Biogen Avonex 63 receptor inhibitor 63 E1 INT TM 63 RNAi Therapeutic 63 Votrient 63 INTEGRILIN R 63 MabThera Rituxan 63 Solid Tumors 63 EOquin TM phase 63 Gastrointestinal Stromal Tumors 63 Avanafil 63 Pegylated Liposomal Doxorubicin 63 APTIVUS R 63 complement inhibitor eculizumab 63 Monoclonal Antibody 63 Is Well Tolerated 63 agomelatine 63 cabazitaxel 63 Mylan Receives Approval 63 Relapsed Refractory Multiple Myeloma 63 Myozyme alglucosidase alfa 63 Canvaxin 63 Fluorouracil 63 Betaseron ® 63 Xinlay 63 Metastatic Renal Cell Carcinoma 63 IMA# 63 Study Evaluating 63 vinca alkaloids 63 Amphotericin B 63 Kinase Inhibitors 63 Advanced Prostate Cancer 63 Vidaza R 63 interferon IFN 63 Alinia 63 Neovascular Age Related Macular 63 Metabolic Disorder 63 B CLL 63 Randomized Phase II 63 Interferon alfa 63 trastuzumab Herceptin 63 Progenitor Cells 63 psoriatic arthritis PsA 63 GRN# 63 biliary tract cancer 63 INVEGA ® SUSTENNA ® 63 Sycrest 63 T#I [002] 63 dual endothelin receptor antagonist 63 AA amyloidosis 63 PSMA ADC 63 antiplatelet agent 63 Troxatyl 63 elvucitabine 63 Advanced Pancreatic Cancer 63 IMiDs R 63 Cx# [002] 63 Slow Progression 63 Interferon Alfa 63 alemtuzumab treated 63 retinal vein occlusion 63 generation purine nucleoside 63 Chronic Heart Failure 63 BioNumerik 63 Initiate Clinical Trial 63 6R BH4 63 metastatic RCC 63 alpha interferons 63 Gleevac 63 midstage clinical 63 ANTEGREN 63 Demonstrates Potent 63 SCIg 63 lymphoid malignancies 63 Pegintron 63 IAP inhibitor 63 mGluR5 NAM 63 Azedra 63 recurrent GBM 63 EGFR TKI 63 Aptamer 63 HuMax CD# 63 Demonstrates Efficacy 63 Refractory Hodgkin Lymphoma 63 Epoetin Alfa 63 small molecule tyrosine 63 Fibrillex TM 63 ZACTIMA TM ZD# 63 ularitide 63 Homspera TM 63 acetonide FA 63 myelodysplastic syndromes